Login to Your Account



Riboquark lands ¥42M to develop siRNA ocular neuroprotectant for glaucoma

By Shannon Ellis
Staff Writer

Wednesday, January 15, 2014

SHANGHAI – The Chinese-American joint venture Kunshan Riboquark Pharmaceutical Technology Co. Ltd. has raised ¥42 million (US$7 million) in venture capital financing to develop QPI-1007, an ocular neuroprotectant that uses small interfering RNA technology (siRNA) to stop the progression of glaucoma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription